-
Relugolix
API Nomen Indicium Innovator Exitus patentibus Date (US) Relugolix cancer prostatae Takeda et Aska 24 Jan -
Vericiguat
API Nomen Indicium Innovator Exitus patentibus Date (US) Vericiguat Cordis defectum Bayer et MSD Kalendas lunii. 24, 2031 -
Abrocitinib
API Nomen Indicium Innovator Exitus patentibus Date (US) Abrocitinib Dermatitis atopic Pfizer Feb. 11, 2034 -
Rimegepant
API Nomen Indicium Innovator Exitus patentibus Date (US) Rimegepant Migraine capitis Biohaven 22 Dec -
Elagolix 834153-87-6
API Nomen Indicium Specification US DMF EU DMF CEP ElagolixCAS;834153-87-6 Endometriosis In-Domus -
Relugolix 737789-87-6
API Nomen Indicium Specification US DMF EU DMF CEP Ribociclib CAS: 737789-87-6 Antineoplastic In-Domus -
Venetoclax 1257044-40-8
API Nomen Indicium Innovator Exitus patentibus Date (US) Venetoclax 1257044-40-8 CLL Abbvie Jun.27,2031 -
Velpatasvir(PVP)
API Nomen Indicium Specification US DMF EU DMF CEP Velpatasvir(PVP) HCV In-Domus √ -
Thalidomide
API Nomen Indicium Specification US DMF EU DMF CEP Thalidomide Oncology medicamento USP/EP -
Ticagrelor
API Nomen Indicium Specification US DMF EU DMF CEP Ticagrelor Anticoagulant In-Domus 28984 √ -
Tofacitnib Citrate
API Nomen Indicium Specification US DMF EU DMF CEP Tofacitnib Citrate Rheumatoid arthritis In-Domus -
Sugammadex Sodium
API Nomen Indicium Specification US DMF EU DMF CEP Sugammadex Sodium Neuromuscular obsidio In-Domus